NTAX-44 : An Oral Arsenic
First, orally administered, indigenously developed Arsenic compound for Glioblastoma (GBM), Acute Promyelocytic Leukemia (APML) and potential for other hematological malignancies and solid tumors.
Why Arsenic ?
- Arsenic has a tremendous anticancer potential which is evident from the fact that there are currently over 100 clinical trials going on in various parts of globe as a mono-therapy as well as in combination with other Biological & Chemical Agents for the treatment of hematologic and solid tumor malignancies.
- Arsenic has well known history of toxicity and current treatments with arsenic have several limitations in terms of the therapy related side effects.
- RBPL successfully removed the dose related toxicity in Arsenic with a unique patented green process keeping its therapeutic properties intact.
Salient Features
- Synthesized by green technology
- Oral Best tolerated in its class
- Smaller particle size favours better bio-availability
- Patent filed, under PCT and all claims accepted to be novel and inventive
Current Status
- Successfully completed Pilot Clinical trial (AYUSH) “A prospective, open label, pilot study to evaluate safety, efficacy and bio- availability of oral Arsenic compound (Somal, NTAX-44 an arsenic based compound) in patients with solid tumors”.
- Currently, under process of Ph II/III submission to DCGI for Glioblastoma (GBM) patients.
- Also, planning for BA/BE studies for Acute Promyelocytic Leukemia (APML).
